320 W 10th Ave
Columbus, OH 43210
Phone: (614) 293-9869
Assistant Professor-Clinical, Hematology
Preceptor: Internal Medicine Clinic- 4 hrs. 1/18/11
Resident morning report preceptor- 1/12/11, 11/17/10, 10/2014
During my final year of hematology and oncology fellowship training at the University of Rochester, I was selected to participate in an intensive week long program sponsored by the American Society of Hematology (ASH) in order to develop skills in patient-oriented clinical research. ASH is the world's largest professional society for clinicians and researchers who care for patients with hematologic disorders, and this program was developed to encourage trainees to pursue a career in academic hematology. It was here that I met Dr. John Byrd and was introduced to the Division of Hematology at OSU, eventually joining the faculty in 2008. My interest then and now is in the development of novel therapeutic agents for patients with myeloid malignancies, specifically acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Currently I am an assistant professor on the clinician scholar track and my assigned clinical effort has been set at 35%.
I approached joining the faculty and beginning a successful career with several goals in mind. First, I planned to learn and then fine tune the skills necessary to build a strong foundation in clinical research. I was able to do this initially with support provided by the K12 CURE supplement, which then allowed me to successfully compete for a national career development award sponsored by ASH and the Robert Wood Johnson Foundation. My research has studied the use of novel agents that target aberrant signaling pathways in AML in the context of phase I clinical trials, and most recently has included determining a safe and tolerable dose that is also biologically effective, an innovative trial design. I have presented my research at the ASH annual meeting and gained further national recognition within this organization with an appointment to the ASH Committee on Promoting Diversity, as well as serving as an abstract reviewer, coordinating abstract reviewer, and oral session moderator. I was also the scientific co-chair for the AML, MDS and Transplantation session at the American Society of Clinical Oncology (ASCO) annual meeting in 2012. ASCO is a national professional oncology society dedicated to clinical oncology, and this session is one of the few that occur during the meeting that is dedicated to hematologic malignancies. Internationally, I successfully applied to establish OSU as a Center of Excellence by the international MDS Foundation and serve as the point of contact for the Foundation. This has led to an increase in patient referrals, as well as provided opportunities to serve as a co-investigator on national and international trials in this disease. I have led 5 investigator initiated studies and been a principal investigator or co-investigator on more than 30 clinical trials. Overall, my work has resulted in more than twenty peer reviewed articles. I have also continued to pursue excellence in the care that I provide to patients and this has been recognized by patient satisfaction scores and awards.
While initially my career was progressing along the tenure track, securing career development awards, it became clear that my interest in clinical research and education were more consistent with my long term goals and I transitioned to the clinical track from the tenure track in March of 2014. This allowed me to fully pursue my second goal, serving as a mentor for students, residents, and fellows. In recognition of this commitment I was asked to become the associate program director of the Hematology and Oncology fellowship program in August 2013, a role that I have transitioned into without difficulty, and I have led three impactful curriculum changes since entering this new position.
I have taken on other leadership roles within the cancer center as an executive member of the Clinical Science Review Committee, and in the College of Medicine as an alternate member of the College of Medicine Faculty Council. In support of furthering my leadership development I was selected to participate in the year long Faculty Leadership Institute sponsored by FAME, and completed this training in March of 2015. Our project was selected as the winning idea, receiving the greatest number of votes from the judges. To further my professional development I also enrolled and completed course requirements for a Master of Public Health in May 2015.
In summary, I have built a solid foundation and have had numerous achievements that are sure to continue in the future.
|2015 - present||John Vaughn, The Ohio State University.|
|2012||Myntee Ngangana, The Ohio State University. Graduated 2013.|
|2005 - present||Medical Doctor (MD): New York State Medical Board|
|2005 - present||Internal Medicine: American Board of Internal Medicine|
|2008 - present||Medical Doctor (MD): State Medical Board of Ohio|
|2008 - present||Hematology: American Board of Internal Medicine|
|2009 - present||Medical Oncology: American Board of Internal Medicine|
|1997 - 2002||Pharmacist (RPh): New York State Medical Board|
Walker AR, Marcucci GM. "Introduction: Genetics and Classification of AML." In Targeted Therapy of Acute Myeloid Leukemia. Edited by Andreef M. -. New York: Springer, January 2014.
|08/01/2008||Hematology Division - Outpatient Clinic (James Cancer Hospital)|
|11/01/2008||Hematology II/ Acute Leukemia Service - Hematology Division - Inpatient service (The James Cancer Hospital)|
|04/01/2014||Hematology IV/ Acute Leukemia and Bone Marrow Transplantation Hematology Division - Inpatient Servic (James Cancer Hospital)|
Abboud CN, Walker A, Komrokji RS, Ifthikharuddin JJ, Sparks C, Likly K, Messina P, Mulford D, Friedberg J, Becker MW, Young F, Bernstein SH, Salvado AJ, Phillips GL, Liesveld JL. "Phase I study of cladribine, cytarabine (Ara-C), Granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simulataneous escalating doses of imantinib mesylate (Gleevac) in relapsed/refractory AML.." In Blood. (November 2006). 1958-.
Liesveld JL, Rosell K, Lu C, Mulford D, Walker A. "The mTOR inhibitor rapamycin demonstrates activity against AML in combination with imatinib mesylate and with 5-azacytidine.." In Blood. (November 2007). 147B-147B.
Chen P, Blum W, Aimiuwu J, Upadhyayula V, Liu Z, Liu S, Pang J, Walker A, Klisovic RB, Garzon R, Grever MR, Villalona-Calero M, Byrd JC, Chan KK, Marcucci G. "Quantification of Intracellular Decitabine-Triphosphate with A Novel, Highly Sensitive and Specific LC-MS/MS Assay in Acute Myeloid Leukemia Patients Treated with Low Dose Decitabine." In Blood. (November 2009). 1454-1455.
Blum W, Klisovic RB, Walker A, Garzon R, Liu S, Schaaf LJ, Humphries K, Grever MR, Devine SM, Byrd JC, Marcucci G. "Epigenetic Targeting Via Transcriptional Inhibition of DNA Methyltransferase: a Phase I Study of Bortezomib in Combination with 5-Azacytidine in Adults with Relapsed or Refractory Acute Myeloid Leukemia (AML)." In Blood. (November 2009). 815-816.
Chandler JC, Klisovic RB, Phelps MA, Walker A, Garzon R, Yang X, Schaaf L, Schwind S, Becker H, Liu S, Hickey C, Kefauver C, Mickle J, Devine SM, Grever MR, Byrd JC, Marcucci G, Blum W. "Phase I Study of Lenalidomide in Acute Leukemia: Remissions in Post-Allogeneic Relapse of Acute Myeloid Leukemia." In Blood. (November 2009). 346-347.
Gojo I, Walker A, Cooper M, Feldman EJ, Padmanabhan S, Baer MR, Poon J, Small K, Zhang D, Sadowska M, Bannerji R. "Phase II Study of the Cyclin-Dependent Kinase (CDK) Inhibitor Dinaciclib (SCH 727965) In Patients with Advanced Acute Leukemias." In Blood. (November 2010). 3287-.
Blum W, Klisovic RB, Garzon R, Walker A, Schwind S, Liu S, Schaaf L, Garr C, Devine SM, Greyer MR, Byrd JC, Marcucci G. "Phase 1 Trial of Decitabine and Bortezomib in High Risk Acute Myeloid Leukemia (AML)." In Blood. (November 2010). 1349-1349.
Klisovic,B; Blum,W; Chen,P; Xie,Z; Liu,S; Walker,A; Devine,S; Garzon,R; Byrd,J; Wetzler,M; Sayar,H; Damon,L; Grosskreutz,C; Solomon,S; Murray,P; Chan,K; Marcucci,G. "A Phase II study of GTI-2040, an Antisense to Ribonucleotide Reductase in Combination with High-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia.." In Haematologica- The Hematology Journal. (June 2010). 27-27.
Walker AR, Metzeler KH, Geyer S, Becker H, Schwind S, Whitman SP, Curfman J, Wu Y-Z, Perrotti D, Klisovic RB, Garzon R, Blum W, Marcucci G. "Impact of DNMT3A mutations on Clinical Response to the Hypomethylating Agent Decitabine in Older Patients (pts) with Acute-Myeloid Leukemia (AML)." In Blood. (November 2011). 430-430.
Wang H, Chen P, Wang J, Santhanam R, Aimiuwu J, Uv V, Liu Z, Schwind S, Mims AS, Klisovic RB, Walker A, Grever MR, Villalona-Calero M, Byrd JC, Garzon R, Blum W, Chan KK, Marcucci G. "Quantification of the Active Decitabine-Triphosphate (DAC-TP) Metabolite: A Novel Pharmacoanalytical Endpoint for Optimization of Hypomethylating Therapy in Acute Myeloid Leukemia (AML)." In Blood. (November 2012). 3578-.
Klisovic RB, Wang H, Walker A, Walsh K, Vasu S, Garzon R, Devine SM, Wang J, Garr C, Norris A, Byrd JC, Grever MR, Blum W, Chan KK, Marcucci G. "Phase I Study of the Combination of Azacitidine (AZA) with MEC (Mitoxantrone, Etoposide and Cytarabine) Salvage Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia (AML): Early Results." In Blood. (November 2012). 3616-.
Liesveld JL, O'Dwyer K, Becker MW, Mulford D, Walker A, Chen R, Bechelli J, Rosell K, Jordan CT, Minhajuddin M, Phillips GL. "Phase I Study of Decitabine and Rapamycin in Relapsed/Refractory Acute Myelogenous Leukemia." In Blood. (November 2012). 3549-.
Blum W, Klisovic RB, Walker A, Schwind S, Jiang Y, Wang J, Phelps M, Geyer S, Devine SM, Walsh K, Vasu S, Curfman JP, Schaaf L, Garr C, Kefauver C, Byrd JC, Grever MR, Garzon R, Marcucci G. "Priming of Mir-181a in Acute Myeloid Leukemia (AML) to Increase Chemosensitivity: A Phase I Trial of Lenalidomide (LEN) Followed by Idarubicin and Cytarabine.." In Blood. (November 2012). 2619-.
Jiang Y, Wang J, Walker A, Li X, Drake A, Schaaf L, Byrd J, Marcucci G, Grever M, Blum W, Phelps M. "Lenalidomide Pharmacokinetics in Combination with Idarubion and Cytarabine in patients with Acute Myeloid Leukemia.." In Clinical Pharmacology and Therapeutics. (February 2013). S66-S67.
|1997||B.S., State University of New York College at Buffalo|
|2002||M.D., University of Rochester|
|2015||M.Public Hlth., The Ohio State University|
|2010 - present||MDS Center of Excellence. MDS Foundation.|
|2010 - 2014||ASH-AMFDP Award. ASH and Robert Wood Johnson Foundation.|
|2011 - present||Med I/II Integrated Pathway Program faculty recognition award. College of Medicine.|
|2013 - present||Who's who in Black Columbus. Who's Who.|
Walker A, Rothberg PG, Liesveld JL. "A case of JAK2 positive essential thrombocythemia 16.5 years after autologous marrow transplantation for AML.." Bone Marrow Transplantation. Vol. 39, (January 2007.): 725-726.
Walker A, Kleiner A, Rich L, Conners C, Fisher R, Anolik J, Friedberg J. "Profound hypogammaglobulinemia 7 years after treatment for indolent lymphoma.." Cancer Invest.. Vol. 4, no. 26. (May 2008.): 431-433.
Walker A, Komrokji R, Ifthikharuddin J, Mulford D, Becker M, Friedberg J, Oliva J, Phillips G, Liesveld J, Abboud C. "Phase I study of Cladribine, Cytarabine (Ara-C), Granylocyte Colony Stimulating Factor (G-CSF) (CLAG Regimen) and Simultaneous Escalating Doses of Imatinib Mesylate (Gleevac) in Relapsed/Refactory AML.." Leuk Res. Vol. 12, no. 32. (January 2008.): 1830-1836.
Blum W, Garzon R, Klisovic R, Schwind S, Walker A, Geyer S, Liu S, Havelange V, Becker H, Schaaf L, Mickle J, Devine H, Kefauver C, Devine S, Chan K, Heerema N, Bloomfield C, Grever M, Byrd J, Villalona-Calero M, Croce C, Marcucci G. "Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine." Proc Natl Acad Sci USA. Vol. 16, no. 107. (April 2010.): 7473-7478.
Blum W, Klisovic R, Becker H, Yang X, Rozewski D, Phelps M, Garzon R, Walker A, Chandler J, Whitman S, Curfman J, Liu S, Schaaf L, Mickle J, Kefauver C, Devine S, Grever M, Marcucci G, Byrd J. "Dose escalation of lenalidomide in relapsed or refractory acute leukemias.." J Clin Oncol.. Vol. 28, (January 2010.): 4919-4925.
Metzeler K, Walker A, Geyer S, Garzon R, Klisovic R, Bloomfield C, Blum W, Marcucci G. "DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia." Leukemia. Vol. 26, (January 2011.): 1106-1107.
Walker A, Marcucci G. "Impact of molecular prognostic factors in cytogenetically normal acute myeloid leukemia at diagnosis and relapse." HAEMATOLOGICA-THE HEMATOLOGY JOURNAL. Vol. 96, no. 5. (May 2011.): 640-643.
Hickey C, Schwind S, Radomska H, Dorrance A, Santhanam R, Mishra A, Wu Y, Alachkar H, Maharry K, Nicolet D, Mrozek K, Walker A, Eiring A, Whitman S, Becker H, Perrotti D, Wu L, Zhao X, Fehniger T, Vij R, Byrd J, Blum W, Lee L, Caligiuri M, Bloomfield C, Garzon R, Marcucci G. "Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein upregulates expression of the anti-leukemic microRNA-181a in acute myeloid leukemia.." Blood. Vol. 10.1182, (October 2012.): 2012-05.
Yan P, Frankhouser D, Murphy M, Tam H, Rodriguez B, Curfman J, Trimarchi M, Geyer S, Wu Y, Whitman S, Metzeler K, Walker A, Klisovic R, Jacob S, Grever M, Byrd J, Bloomfield C, Garzon R, Blum W, Caligiuri M, Bundschuh R, Marcucci G. "Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia.." Blood. Vol. 120(12), (July 2012.): 2466-74.
Racke F, Cole C, Walker A, Jones J, Heerema N. ". Therapy-related pro-B cell acute lymphoblastic leukemia: report of two patients with MLL amplification." Cancer Genetics. Vol. 0, (December 2012.): 0-.
Walker A, Marcucci G. "Molecular prognostic factors in cytogenetically normal acute myeloid leukemia.." Expert Rev Hematol.. Vol. 5(5), (October 2012.): 547-58.
Wang H, Chen P, Wang J, Santhanam R, Aimiuwu J, Saradhi U, Liu Z, Schwind S, Mims A, Byrd J, Grever M, Villalona-Calero M, Klisovic R, Walker A, Garzon R, Blum W, Chan K, Marcucci G. "In Vivo Quantification of Active Decitabine-Triphosphate Metabolite: A Novel Pharmacoanalytical Endpoint for Optimization of Hypomethylating Therapy in Acute Myeloid Leukemia.." AAPS J. Vol. Doi: 10.1208/S12248-012-9427-5, (November 2012.): 1-8.
Tallman M, Chung S, Damon L, Marcucci G, Walker A, Madhava B. "75-year-old woman with Thoracic Spinal Cord Compression and Chloroma (Granulocytic Sarcoma).." Seminars in Oncology. Vol. 39, (December 2012.): e37-e46.
Blum W, Schwind S, Tarighat S, Geyer S, Eisfeld A, Whitman S, Walker A, Klisovic R, Byrd J, Santhanam R, Wang H, Curfman J, Devine S, Jacob S, Garr C, Kefauver C, Perrotti D, Chan K, Bloomfield C, Caligiuri M, Grever M, Garzon R, Marcucci G. "Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia." BLOOD. Vol. 119, no. 25. (June 2012.): 6025-6031.
Ranganathan P, Yu X, Na C, Santhanam R, Shacham S, Kauffman M, Walker A, Klisovic R, Blum W, Caligiuri M, Croce C, Marcucci G, Garzon R. "Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia.." Blood. Vol. 120, no. 9. (August 2012.): 1765-1773.
Walker A, Mrozek K, Kohlschmidt J, Rao K, Pettenati M, Sterling L, Marcucci G, Carroll A, Bloomfield C. "New recurrent balanced translocations in acute myeloid leukemia and myelodysplastic syndromes: Cancer and leukemia group B 8461." GENES CHROMOSOMES & CANCER. Vol. 52, no. 4. (April 2013.): 385-401.
Mims A, Walker A, Huang X, Sun J, Wang H, Santhanam R, Dorrance AM, Walker C, Hoellerbauer P, Tarighat S, Chan K, Klisovic R, Perrotti D, Caligiuri M, Byrd J, Chen C-S, Lee L, Jacob S, Mrozek K, Bloomfield C, Blum W, Garzon R, Schwind S, Marcucci G. "Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia." LEUKEMIA. Vol. 27, no. 4. (April 2013.): 871-878.
Huang X, Schwind S, Yu B, Santhanam R, Wang H, Hoellerbauer P, Mims A, Klisovic R, Walker A, Chan K, Blum W, Perrotti D, Byrd J, Bloomfield C, Caligiuri M, Lee R, Garzon R, Muthusamy N, Lee L, Marcucci G. "Targeted Delivery of microRNA-29b by Transferrin-Conjugated Anionic Lipopolyplex Nanoparticles: A Novel Therapeutic Strategy in Acute Myeloid Leukemia." CLINICAL CANCER RESEARCH. Vol. 19, no. 9. (May 2013.): 2355-2367.
Walker A, Klisovic R, Johnston J, Jiang Y, Geyer S, Kefauver C, Binkley P, Byrd J, Grever M, Garzon R, Phelps M, Marcucci G, Blum K, Blum W. "Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia." LEUKEMIA & LYMPHOMA. Vol. 54, no. 9. (September 2013.): 1996-2002.
Gojo I, Sadowska M, Walker A, Feldman E, Iyer S, Baer M, Sausville E, Lapidus R, Zhang D, Zhu Y, Jou Y, Poon J, Small K, Bannerji R. "Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias." CANCER CHEMOTHERAPY AND PHARMACOLOGY. Vol. 72, no. 4. (October 2013.): 897-908.
Liesveld J, O'Dwyer K, Walker AR, Becker M, Ifthikharuddin J, Mulford D, Chen R, Bechelli J, Rosell K, Minhajuddin M, Jordan C, Phillips G. "A phase I study of decitabine and rapamycin in relapsed/refractory AML." LEUKEMIA RESEARCH. Vol. 37, no. 12. (December 2013.): 1622-1627.
Walker AR, Marcucci G. "Management of Patients With Cytogenetically Normal Acute Myeloid Leukemia Who Have Neither Favorable nor Unfavorable Markers." JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK. Vol. 12, no. 4. (April 2014.): 527-534.
Walker AR, Klisovic R, Garzon R, Schaaf L, Humphries K, Devine S, Byrd J, Grever M, Marcucci G, Blum W. "Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia." LEUKEMIA & LYMPHOMA. Vol. 55, no. 6. (June 2014.): 1304-1308.
"DNMT Mutations and Response to Decitabine." Presented at CALGB, Chicago. (September 2011)
"Targeting the Expression of Mutated genes encoding Tyrosine Kinases in Acute Myeloid Leukemia." Presented at Harold Amos Medical Faculty Development Program, New Orleans. (October 2011)
"Impact of DNMT3A Mutations in AML patients treated with Decitabine." Presented at CALGB, Chicago. (November 2011)
"Leukemia, Myelodysplasia, and Transplantation." Presented at American Society of Clinical Oncology Annual Meeting, Chicago, IL. (May 2012)
"Acute Myeloid Leukemia: Therapy, excluding Transplantation: Translational Studies." Presented at American Society of Hematology Annual Meeting, New Orleans, Louisiana. (December 2013)
"Targeting the Expression of Mutated genes encoding Tyrosine Kinases in Acute Myeloid Leukemia." Presented at Harold Amos Medical Faculty Development Program, . (October 2013)
|present||CDK Acute Leukemia Advisory Board. Schering-Plough.|
|present||Dicussing Myeloid Diseases. It's All About Health Radio Show.|
|present||OSUCCC IRP Population Science Review.|
|present||OSUCCC IRP Population Science Reivew.|
|present||T32 Oncology Training Grant Review Committee.|
|present||Community Health Day. The Ohio State University.|
|present||ARNO Advisory Board Meeting. Arno Therapeutics.|
|present||Community Health Day. OSU Medical Center.|
|2000 - 2002||Hospice. Rochester, NY.|
|- 2012||Health Seminar Speaker. Friendship Missionary Baptist Church. Columbus, OH.|
|- 2012||Myelodysplastic Syndrome Broadcast. WBNS/TV-10.|
|- 2012||The Black History Month Program.|
|- 2012||TKI vs. imatinib for first line treatment in CML. HemOnc Today Newspaper.|
|- 2012||MDS Awareness. WCMH/TV-4.|
|- 2012||Doctor Day Hotline.|